Send us a text

The COVID-19 conversation continues with the group focusing on challenges in clinical trial execution and how innovative logistics and consistent education can lessen or overcome them.

In this conversation, the group starts by discussing the significant number of patients who could benefit from NAFLD or NASH therapy centered around defatting the liver through medications and behavioral support and proceeds to address ways to manage these issues in a pandemic for a disease with no approved medications. Louise discusses the importance of broad monitoring for patients who might have an early-stage disease, Stephen comments on the importance of education and Manal provides examples of successful "out-of-the-box" patient management programs such as simple home-based "Lab and Leave" visits. The conversation is filled with real passion and enthusiasm for solving new challenges.